Bispecific anti-PD-1/LAG-3 antibodies for treatment of advanced or metastatic solid tumors: a patent evaluation of US2018326054
Sign Up to like & getrecommendations! Published in 2020 at "Expert Opinion on Therapeutic Patents"
DOI: 10.1080/13543776.2020.1767071
Abstract: ABSTRACT Introduction Due to the primary role of PD-1 and LAG-3 in regulating the immune response in tumors, there is a need to develop therapies focused on the inhibition of PD-1 and LAG-3 in order… read more here.
Keywords: anti lag; lag antibodies; treatment; lag ... See more keywords
Abstract LB194: A small molecular-weight anti-lag-3 peptide inhibits colon tumor growth
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-lb194
Abstract: Lymphocyte activation gene-3 (LAG-3) has emerged as a promising target for cancer immunotherapy. It is expressed on activated CD4+ and CD8+ T cells, and on the surface of B cells, natural killer cells, and dendritic… read more here.
Keywords: growth; small molecular; anti lag; tumor ... See more keywords
Updated phase I trial of anti-LAG-3 or anti-CD137 alone and in combination with anti-PD-1 in patients with recurrent GBM.
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2019.37.15_suppl.2017
Abstract: 2017 Background: Preclinical GBM data targeting the checkpoint molecules Lag-3 and CD137 have shown promising anti-tumor immune response with resultant improved survival when combined with anti-PD-1. Here we report our experience from a multi-arm safety… read more here.
Keywords: anti cd137; combination; anti lag;